Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

NORDIHYDROGUARETIC ACID

Unique Identifier:SPE01502206
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:C18H22O4
Molecular Weight:280.19 g/mol
X log p:14.138  (online calculus)
Lipinksi Failures1
TPSA0
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:4
Rotatable Bond Count:5
Canonical Smiles:CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1
Source:ex Larrea divaricata
Reference:J Am Pharm Sci 34: 78 (1945)
Therapeutics:lipoxygenase inhibitor, antioxidant
Generic_name:Masoprocol
Chemical_iupac_name:4-[4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
Drug_type:Approved Drug
Pharmgkb_id:PA450325
Kegg_compound_id:C10719
Drugbank_id:APRD01084
Melting_point:185.5 oC
Logp:4.018
Cas_registry_number:500-38-9
Drug_category:Antineoplastics, topical; Antioxidants; Cyclooxygenase Inhibitors; Keratolytic
Agents; Lipoxygenase Inhibitors; ATC:L01XX10
Indication:Used for the treatment of actinic keratoses (precancerous skin growths that can
become malignant if left untreated).
Pharmacology:Masoprocol is a novel antineoplastic agent. It is not known exactly how masoprocol
works. Laboratory experiments have shown that masoprocol prevents cells similar to
the ones found in actinic keratoses from multiplying. Masoprocol was withdrawn from
the U.S. market in June 1996.
Mechanism_of_action:Although the exact mechanism of action is not known, studies have shown that
masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity
against keratinocytes in tissue culture, but the relationship between this activity
and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits
prostaglandins but the significance of this action is not yet known.
Organisms_affected:Humans and other mammals

Found: 60 active | as graph: single | with analogs [1] << Back 51 52 53 54 55 56 57 58 59 60 Next >> [60]
Species: 4932
Condition: VPS1
Replicates: 2
Raw OD Value: r im 0.5656±0.00572756
Normalized OD Score: sc h 0.8819±0.0132161
Z-Score: -4.6700±0.371781
p-Value: 0.00000564338
Z-Factor: -2.81191
Fitness Defect: 12.085
Bioactivity Statement: Active
Experimental Conditions
Library:Spectrum
Plate Number and Position:9|C9
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:24.90 Celcius
Date:2007-10-03 YYYY-MM-DD
Plate CH Control (+):0.040175±0.00097
Plate DMSO Control (-):0.621425±0.06173
Plate Z-Factor:0.6453
png
ps
pdf

DBLink | Rows returned: 5
4534 4-[4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
71398 4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
688035 4-[(2S,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
688036 4-[(2R,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
5317328 4-[(2R,3S)-4-(4-hydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol

internal high similarity DBLink | Rows returned: 1
LOPAC 01089 1.0000

nonactive | Cluster 12980 | Additional Members: 10 | Rows returned: 72 Next >> 
LOPAC 01089 0.55
LOPAC 00584 0.365853658536585
LOPAC 00822 0.365853658536585
SPE02300205 0
LAT005E02 0
Prest185 0

Service provided by the Mike Tyers Laboratory